Nonhuman Mammalian Retroviruses

  • Steven Specter
  • Mauro Bendinelli
  • Herman Friedman
Part of the Infectious agents and pathogenesis book series (IAPA)


It is beyond the scope of this chapter to present a comprehensive discussion of the biology of mammalian retroviruses. This has been reviewed effectively elsewhere.(1,2) The brief overview provided here focuses on the aspects of retrovirus biology that may assist in understanding the effects of these viruses on immunity.


Leukemia Virus Acquire Immune Deficiency Syndrome Bovine Leukemia Virus Mouse Mammary Tumor Virus Equine Infectious Anemia Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Weiss, R., N. Teich, N. Varmus, and J. Coffin (eds.), RNA Tumor Viruses: Molecular Biology of Tumor Viruses ,2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1985).Google Scholar
  2. 2.
    Lowy, D. R., Transformation and oncogenesis: Retroviruses, in: Virology (B. N. Fields, D. M. Knipe, R. M. Chanock, J. L. Melnick, B. Roizman, and R. E. Shope, eds.), pp. 235–263, Raven, New York (1985).Google Scholar
  3. 3.
    Mosier, D. E., R. A. Yetter, and H. C. Morse III, Retroviral induction of acute lympho-proliferative disease and profound immunosuppression in adult C57BL/6 mice, J. Exp. Med. 161:766–784 (1985).PubMedCrossRefGoogle Scholar
  4. 4.
    Notkins, A. L., S. E. Mergenhagen, and R. J. Howard, Effect of virus infections on the function of the immune system, Annu. Rev. Microbiol. 24:525–538 (1970).PubMedCrossRefGoogle Scholar
  5. 5.
    Dent, P. B., Immunodepression by oncogenic viruses, Prog. Med. Virol. 14:1–35 (1972).PubMedGoogle Scholar
  6. 6.
    Dent, P. B., Immunodepression by oncogenic viruses, in: The Immune System and Infectious Diseases, Fourth International Convocation of Immunology, Buffalo, N.Y. pp. 95–107, Karger, Basel (1975).Google Scholar
  7. 7.
    Specter, S., and H. Friedman, Viruses and the immune response, Pharmacol. Ther. A 2:595–622 (1978).Google Scholar
  8. 8.
    Bendinelli, M., D. Matteucci, and H. Friedman, Retrovirus-induced acquired immu nodeficiencies, Adv. Cancer Res. 45:125–181 (1985).PubMedCrossRefGoogle Scholar
  9. 9.
    Desrosiers, R. C., and N. L. Letvin, Animal models for acquired immunodeficiency syndrome, Rev. Infect. Dis. 9:438–446 (1987).PubMedCrossRefGoogle Scholar
  10. 10.
    Peterson, R. D. A., R. Hendrickson, and R. A. Good, Reduced antibody forming capacity during the incubation period of passage A leukemia in C3H mice, Proc. Soc. Exp. Biol. Med. 114:517–520 (1966).Google Scholar
  11. 11.
    Odaka, T., H. Ishii, K. Yamaura, and T. Yamamoto, Inhibitory effect of Friend leukemia virus infection on the antibody formation to sheep erythrocytes in mice, Jpn. J. Exp. Med. 36:277–290 (1967).Google Scholar
  12. 12.
    Salaman, M. H., and N. Wedderburn, The immunodepressive effects of Friend virus, Immunology 10:445–448 (1966).Google Scholar
  13. 13.
    Ceglowski, W. S., and H. Friedman, Suppression of the primary antibody plaque response of mice following infection with Friend disease virus, Proc. Soc. Exp. Biol. Med. 126:662–666 (1967).Google Scholar
  14. 14.
    Ceglowski, W. S., and H. Friedman, Immunosuppression by leukemia viruses. I. Effect of Friend disease virus on cellular and humoral hemolysin response of mice to a primary immunization with sheep erythrocytes, J. Immunol. 101:594–604 (1968).PubMedGoogle Scholar
  15. 15.
    Hirano, S., W. S. Ceglowski, J. L. Allen, and H. Friedman, Effect of Friend leukemia virus on antibody forming cells to a bacterial antigen, J. Natl. Cancer Inst. 43:1337–1345 (1969).PubMedGoogle Scholar
  16. 16.
    Morrison, R. D., J. Nishio, and B. Chesebro, Influence of the murine MHC (H-2) on Friend leukemia virus-induced immunosuppression, J. Exp. Med. 163:301–314 (1986).PubMedCrossRefGoogle Scholar
  17. 17.
    Bainbridge, D. R., and M. Bendinelli, Circulation of lymphoid cells in mice infected with Friend leukemia virus, J. Natl Cancer Inst. 49:773–781 (1972).PubMedGoogle Scholar
  18. 18.
    Friedman, H., and W. S. Ceglowski, Virus tumorigenesis and immunity: Influence of immunostimulation and immunodepression, in: The Role of Immunologic Factors in Viral and Oncogenic Processes (R. F. Beers, R. C. Tilghman, and E. G. Bassett, eds.), pp. 187– 210, Johns Hopkins University Press, Baltimore (1974).Google Scholar
  19. 19.
    Zatz, M. M., A. White, and A. L. Goldstein, Lymphocyte populations of AKR/J mice. II. Effect of leukemogenesis on migration patterns, response to PHA and expression of theta antigen, J. Immunol. 111:1519–1525 (1973).PubMedGoogle Scholar
  20. 20.
    Koo, G. C., W. S. Ceglowski, and H. Friedman, Immunosuppression by leukemia vi ruses. V. Ultrastructural studies of antibody forming spleens of mice infected with Friend leukemia virus, J. Immunol. 106:799–814 (1971).PubMedGoogle Scholar
  21. 21.
    Koo, G. C., W. S. Ceglowski, and H. Friedman, Immunosuppression by leukemia viruses. VI. Ultrastructure of individual antibody-forming cells in the spleens of Friend leukemia virus-infected mice, J. Immunol 106:815–830 (1971).PubMedGoogle Scholar
  22. 22.
    Bendinelli, M., and L. Nardini, Immunodepression by Rowson-Parr virus in mice. II. Effect of Rowson-Parr virus infection on the antibody response to sheep red blood cells in vivo and in vitro, Infect. Immun. 7:160–166 (1978).Google Scholar
  23. 23.
    Kateley, J. R., I. Kamo, G. Kaplan, and H. Friedman, Suppressive effect of leukemia virus-infected lymphoid cells on in vitro immunization of normal splenocytes, . Natl. Cancer Inst. 53:1371–1378 (1974).Google Scholar
  24. 24.
    Weislow, O. S., and E. F. Wheelock, Depression of humoral immunity to sheep erythrocytes in vitro by Friend virus leukemic spleen cells: Induction of resistance by statolon, J. Immunol 114:211–215 (1975).PubMedGoogle Scholar
  25. 25.
    Specter, S., N. Patel, and H. Friedman, Immunosuppression induced in vitro by cell-free extracts of Friend leukemia virus infected splenocytes, J. Natl Cancer Inst. 56:143–147 (1976).PubMedGoogle Scholar
  26. 26.
    Friedman, H., H. Melnick, L. Mills, and W. S. Ceglowski, Depressed allograft immunity in leukemia virus infected mice, Transplant. Proc. 5:981–986 (1973).PubMedGoogle Scholar
  27. 27.
    Mortensen, R. F., W. S. Ceglowski, and H. Friedman, Leukemia virus induced immunosuppression. IX. Depression of delayed hypersensitivity and MIF production after infection of mice with Friend leukemia virus, J. Immunol. 111:1810–1819 (1973).PubMedGoogle Scholar
  28. 28.
    Deodhar, S. D., and T. Chiang, Immunosuppression with Friend virus in an allogeneic murine tumor system, Fed. Proc. 29:560 (1970).Google Scholar
  29. 29.
    Mortensen, R. F., W. S. Ceglowski, and H. Friedman, Leukemia virus induced immunosuppression. X. Depression of T cell-mediated cytotoxicity after infection with Friend leukemia virus, J. Immunol. 112:2077–2086 (1973).Google Scholar
  30. 30.
    Kateley, J. R., J. Holderbach, and H. Friedman, Leukemia virus induced alteration of lymphocyte Ig surface receptors and ’capping’ response of mouse spleen and lymph node cells, J. Natl. Cancer Inst. 53:1135–1141 (1974).PubMedGoogle Scholar
  31. 31.
    Farber, P., S. Specter, and H. Friedman, Leukemia virus induced immune suppression. Scanning electron microscopy of infected spleen cells, Science 160:467–471 (1975).Google Scholar
  32. 32.
    Kitagawa, M., O. Matsubara, and T. Kasuga, Dynamics of lymphocytic subpopulations in Friend leukemia virus-induced leukemia, Cancer Res. 46:3034–339 (1986).PubMedGoogle Scholar
  33. 33.
    Glendhill, A. W., Enhancement of the pathogenicity of mouse hepatitis virus (MHV) by prior infection of mice with certain leukemia agents, Br. J. Cancer 15:531–538 (1961).CrossRefGoogle Scholar
  34. 34.
    Chirigos, M. A., K. Perk, W. Turner, B. Burka, and M. Gomez, Increased oncogenicity of the murine sarcoma virus (Moloney) by co-infection with murine leukemia virus, Cancer Res. 28:1055–1063 (1968).PubMedGoogle Scholar
  35. 35.
    Specter, S., F. Basolo, and M. Bendinelli, Retroviruses as immunosuppressive agents, in: The Nature, Cellular, and Biochemical Basis and Management of Immunodeficiencies (R. A. Good and E. Lindenlaub, eds.), pp. 128–145, Schattauer Verlag, Stuttgart, (1987).Google Scholar
  36. 36.
    Ceglowski, W. S., G. U. Labadie, and A. A. Mascio, Effects of leukemia viruses on cellular immune responses, in: Tumor Virus Infections and Immunity (R. L. Crowell, H. Friedman, and J. Prier, eds.), pp. 165–173, University Park Press, Baltimore (1976).Google Scholar
  37. 37.
    Old, L., B. Benacerraf, D. A. Clark, and M. Goldsmith, The reticuloendothelial system and the neoplastic process, Ann. NY Acad. Sci. 88:264–280 (1960).CrossRefGoogle Scholar
  38. 38.
    Wheelock, E. F., S. T. Toy, O. S. Weislow, and M. H. Levy, Restored immune and nonimmune functions in Friend virus leukemic mice treated with statolon, Prog. Exp. Tumor Res. 19:369–390 (1974).PubMedGoogle Scholar
  39. 39.
    Seidel, H. J., and W. Nothdurft, The phagocytic activity of the reticuloendothelial system of mice infected with Rauscher leukemia virus, J. Reticuloendothel. Soc. 19:173– 181 (1976).PubMedGoogle Scholar
  40. 40.
    Kirchner, H., T. M. Chused, R. B. Herberman, H. T. Holden, and H. Lavrin, Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus, J. Exp. Med. 139:1473–1478 (1974).PubMedCrossRefGoogle Scholar
  41. 41.
    Moody, D. J., S. Specter, M. Bendinelli, and H. Friedman, Suppression of natural killer cell activity by Friend murine leukemia virus, J. Natl. Cancer Inst. 72:1349–1356 (1984).PubMedGoogle Scholar
  42. 42.
    Bendinelli, M., The reticuloendothelial system in infection with RNA tumor viruses, in: The Reticuloendothelial System: A Comprehensive Treatise ,Vol. 10: Infection (M. Escobar and J. P. Utz, eds.), pp. 297–347, Plenum, New York (1988).Google Scholar
  43. 43.
    Bendinelli, M., G. S. Kaplan, and H. Friedman, Reversal of leukemia virus induced immunosuppression in vitro:1122 Role of peritoneal exudate macrophages, J. Natl. Cancer Inst. 55:1425–1432 (1975).PubMedGoogle Scholar
  44. 44.
    Specter, S., N. Patel, and H. Friedman, Peritoneal exudate cell induced restoration of antibody formation by leukemia virus suppressed spleen cell cultures, Proc. Soc. Exp. Biol. Med. 151:163–167 (1976).PubMedGoogle Scholar
  45. 45.
    Ceglowski, W. S., and H. Friedman, Failure of peritoneal exudate macrophages to reverse immunologic impairment induced by Friend leukemia virus, Proc. Soc. Exp. Biol. Med. 148:808–811 (1975).PubMedGoogle Scholar
  46. 46.
    Genovesi, E. V., D. Livnat, and J. J. Collins, Immunotherapy of murine leukemia. VII. Prevention of Friend leukemia virus induced immunosuppression by passive serum therapy, Int. J. Cancer 30:609–624 (1982).PubMedCrossRefGoogle Scholar
  47. 47.
    Demaeyer-Guignard, J., Mouse leukemia: Depression of serum interferon production, Science 177:797–799 (1972).CrossRefGoogle Scholar
  48. 48.
    Butler, R. C., J. M. Frier, M. S. Chapekar, M. O. Graham, and H. Friedman, Role of antibody response helper factors in immunosuppressive effects of Friend leukemia virus, Infect. Immun. 39:1260–1264 (1983).PubMedGoogle Scholar
  49. 49.
    Bendinelli, M., D. Matteucci, A. M. Giangregorio, and P. G. Conaldi, Restoration of antibody responsiveness by endotoxin in retrovirus-immunosuppressed mice: Role of macrophages, in: Immunobiology and Immunopharmacology of Bacterial Endotoxins (A. Szentivanyi and H. Friedman, eds.), pp. 465–478, Plenum, New York (1986).Google Scholar
  50. 50.
    Lopez-Cepero, M., S. Specter, D. Matteucci, H. Friedman, and M. Bendinelli, Altered interleukin production during Friend leukemia virus infection. Proc. Soc. Exp. Biol. Med. 188:353–363 (1988).PubMedGoogle Scholar
  51. 51.
    Perryman, L. E., E. A. Hoover, and D. S. Yohr, Immunologic reactivity of the cat: Immunosuppression in experimental feline leukemia, J. Natl. Cancer Inst. 49:1357–1365 (1972).PubMedGoogle Scholar
  52. 52.
    Wernicke, D., Z. Trainin, H. Ungar-Waron, and M. Essex, Humoral immune response of asymptomatic cats naturally infected with feline leukemia virus, J. Virol. 60:669–673 (1986).PubMedGoogle Scholar
  53. 53.
    Hardy, W. D., and M. Essex, FeLV-induced feline acquired immune deficiency syn drome. A model for human AIDS, Prog. Allergy 37:353–376 (1986).PubMedGoogle Scholar
  54. 54.
    Pack, F. D., and W. L. Chapman, Light and electron microscopic evaluation of thymuses from feline leukemia virus-infected kittens, Exp. Pathol. 18:96–110 (1980).Google Scholar
  55. 55.
    Orosz, C. G., N. E. Zinn, R. G. Olsen, and L. E. Mathes, Retrovirus mediated immunosuppression. I. FeLV-UV and specific FeLV proteins alter T lymphocyte behavior by inducing hyporesponsiveness to lymphokines, J. Immunol. 134:3396–3403 (1985).PubMedGoogle Scholar
  56. 56.
    Yasuda, M., R. A. Good, and N. K. Day, Influence of inactivated feline retrovirus on feline alpha interferon and immunoglobulin production, Clin. Exp. Immunol. 69:240– 245 (1987).PubMedGoogle Scholar
  57. 57.
    Hebebrand, L. C., R. G. Olsen, L. E. Mathes, and W. S. Nichols, Inhibition of human lymphocyte mitogen and antigen response by a 15,000 dalton protein from feline leukemia virus, Cancer Res. 39:443–447 (1979).PubMedGoogle Scholar
  58. 58.
    Lafrado, L. J. ,M. G. Lewis, L. E. Mathes, and R. G. Olsen, Suppression of in vitro neutrophil function by feline leukemia virus (FeLV) and purified FeLV-p15, J. Gen. Virol. 68:507–513 (1987).PubMedCrossRefGoogle Scholar
  59. 59.
    Mullins, J. I., C. S. Chen, and E. A. Hoover, Disease-specific and tissue-specific production of unintegrated feline leukemia virus variant DNA in feline AIDS, Nature (Lon.) 319:333–336 (1986).CrossRefGoogle Scholar
  60. 60.
    Pedersen, N. C., E. W. Ho, M. L. Brown, and J. K. Yamamoto, Isolation of a T lymphotropic virus from domestic cats with an immunodeficiency-like syndrome, Science 235:790–793 (1987).PubMedCrossRefGoogle Scholar
  61. 61.
    Celer, V., L. Cerny, E. Jelinkova, and P. Nedbal, Absence of primary immune response in acute bovine lymphatic leukemia. I. Occurrence of natural antibodies against E. coli, Neoplasma 18:523–528 (1971).PubMedGoogle Scholar
  62. 62.
    Trainin, Z., H. Ungar-Waron, R. Mairon, A. Barma, and M. Sela, IgG and IgM antibodies in normal and leukaemic cattle, J. Comp. Pathol. 86:571–580 (1976).PubMedCrossRefGoogle Scholar
  63. 63.
    Thorne, R. M., P. Gupta, S. J. Kenyon, and J. F. Ferrer, Evidence that the spontaneous blastogenesis of lymphocytes from bovine leukemia virus-infected cattle is viral antigen specific, Infect. Immun. 34:84–89 (1981).Google Scholar
  64. 64.
    Burny, A., C. Bruck, Y. Cleuter, D. Couez, J. Deschamps, J. Chysdael, D. Gregoire, R. Kettmann, M. Mammerickx, G. Marbaix, and D. Portetelle, Bovine leukemia virus: A new model of leukemogenesis, in: Advances in Viral Oncology ,Vol. 5: Viruses as the Causative Agents of Naturally Occurring Tumors (G. Klein, ed.), pp. 35–56, Raven, New York (1985).Google Scholar
  65. 65.
    Gonda, M. A., M. J. Braun, S. G. Carter, T. A. Kost, J. W., Jr. Bess, L. O. Arthur, and M. J. Van Der Marten, Characterization and molecular cloning of a bovine lentivirus related to human immunodeficiency virus, Nature (Lond.) 330:388–391 (1987).CrossRefGoogle Scholar
  66. 66.
    Haase, A. T., Pathogenesis of lentivirus infections, Nature (Lond.) 322:130–136 (1986).CrossRefGoogle Scholar
  67. 67.
    Narayan, O., J. S. Wolinsky, J. E. Clements, J. D. Strandberg, D. E. Griffin, and L. C. Cork, Slow virus replication: The role of macrophages in the persistence and expression of visna viruses of sheep and goats, J. Gen. Virol. 53:345–356 (1982).CrossRefGoogle Scholar
  68. 68.
    Anderson, L. W., P. Klevjer-Anderson, and H. D. Liggitt, Susceptibility of blood-derived monocytes and macrophages to caprine arthritis encephalitis virus, Infect. Immun. 41:837–840 (1983).PubMedGoogle Scholar
  69. 69.
    Narayan, O., S. Kennedy-Stoskopf, D. Sheffer, D. E. Griffin, and J. E. Clements, Activation of caprine arthritis-encephalitis virus expression during maturation of monocytes to macrophages, Infect. Immun. 41:67–73 (1983).PubMedGoogle Scholar
  70. 70.
    Gendelman, H. E., O. Narayan, S. Kennedy-Stoskopf, J. E. Clements, and G. H. Pezeshkour, Slow virus-macrophage interactions: Characterization of a transformed cell line of sheep alveolar macrophages that express a marker for susceptibility to ovine-caprine lentivirus infections, Lab. Invest. 51:547–555 (1984).PubMedGoogle Scholar
  71. 71.
    Gendelman, H. E., O. Narayan, S. Molineaux, J. E. Clements, and Z. Ghotbi, Slow, persistent replication of lentiviruses: Role of tissue macrophages and macrophage pre cursors in bone marrow, Proc. Natl. Acad. Sci. USA 82:7086–7090 (1985).PubMedCrossRefGoogle Scholar
  72. 72.
    Kennedy, P. G. E., O. Narayan, Z. Ghotbi, J. Hopkins, H. E. Gendelman, and J. E. Clements, Persistent expression of Ia antigen and viral genome in visna-maedi virus induced inflammatory cells: Possible role of lentivirus-induced interferon, J. Exp. Med. 162:1970–1982 (1985).PubMedCrossRefGoogle Scholar
  73. 73.
    Narayan, O., D. Sheffer, J. E. Clements, and G. Tennekoon, Restricted replication of lentiviruses: Visna viruses induce a unique interferon during interaction between lymphocytes and infected macrophages, J. Exp. Med. 162:1954–1969 (1985).PubMedCrossRefGoogle Scholar
  74. 74.
    Gendelman, H. E., O. Narayan, S. Kennedy-Stoskopf, P. G. E. Kennedy, Z. Ghotbi, J. E. Clements, J. Stanley, and G. Pezeshkpour, Tropism of sheep lentiviruses for monocytes: Susceptibility to infection and virus gene expression increase during maturation of monocytes to macrophages, J. Virol. 58:67–74 (1986).PubMedGoogle Scholar
  75. 75.
    Svennerholm, B., O. Strannegard, and E. Lycke, Immune reactivity of visna virus-inoculated mice, Infect. Immun. 20:412–417 (1978).PubMedGoogle Scholar
  76. 76.
    Salinovich, O., S. L. Payne, R. C. Montelaro, K. A. Hussain, C. J. Issel, and K. L. Schnorr, Rapid emergence of novel antigenic and genetic variants of equine infectious anemia virus during persistent infection, J. Virol. 57:71–80 (1986).PubMedGoogle Scholar
  77. 77.
    Banks, K. L., and J. B. Henson, Quantitation of immunoglobulin-bearing lymphocytes and lymphocyte response to mitogens in horses persistently infected by equine infectious anemia virus, Infect. Immun. 8:679–682 (1973).PubMedGoogle Scholar
  78. 78.
    Henson, J. B., and T. C. McGuire, Equine infectious anemia, Prog. Med. Virol. 18:143– 159 (1974).PubMedGoogle Scholar
  79. 79.
    McGuire, T. C., Suppression of synthesis of an IgG subclass in a persistent viral infection, Immunology 30:17–24 (1976).PubMedGoogle Scholar
  80. 80.
    Fujimiya, Y., L. E. Perryman, and T. B. Crawford, Leukocyte cytotoxicity in a persistent virus infection: Presence of direct cytotoxicity but absence of antibody-dependent cellular cytotoxicity in horses infected with equine infectious anemia virus, Infect. Immun. 24:628–636 (1979).PubMedGoogle Scholar
  81. 81.
    Cheevers, W. R., and T. C. McGuire, Equine infectious anemia virus: Immunopathoge-nesis and persistence, Rev. Infect. Dis. 7:84–150 (1985).CrossRefGoogle Scholar
  82. 82.
    Henson, J. B., and T. C. McGuire, Immunopathology of equine infectious anemia, Am. J. Clin. Pathol. 56:306–314 (1971).PubMedGoogle Scholar
  83. 83.
    Teich, N., Taxonomy of retroviruses, in: RNA Tumor Viruses: Molecular Biology of Tumor Viruses ,2nd ed. (R. Weiss, N. Teich, H. Varmus, and J. Coffin, eds.), pp. 1–16, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1985).Google Scholar
  84. 84.
    Fine, D. L., J. C. Landon, R. J. Pienta, M. T. Kubicek, M. J. Valerio, W. G. Loeb, and H. C. Chopra, Responses of infant rhesus monkeys to inoculation with Mason-Pfizer monkey virus material, J. Natl. Cancer Inst. 54:651–658 (1975).PubMedGoogle Scholar
  85. 85.
    Gardner, M. B., and P. A. Marx, Simian acquired immunodeficiency syndrome, in: Advances in Viral Oncology ,Vol. 5: Viruses as the Causative Agents of Naturally Occurring Tumors (G. Klein, ed.), pp. 57–82, Raven, New York (1985).Google Scholar
  86. 86.
    Power, M. D., P. A. Marx, M. L. Bryant, M. B. Gardner, P. J. Barr, and P. A. Luciw, Nucleotide sequence of RSV-1, a type D simian acquired immune deficiency retrovirus, Science 231:1567–1572 (1986).Google Scholar
  87. 87.
    Sonigo, P., C. Barker, E. Hunter, and S. Wain-Hobson, Nucleotide sequence of Mason-Pfizer monkey virus: An immunosuppressive type D retrovirus, Cell 45:375–385 (1986).PubMedCrossRefGoogle Scholar
  88. 88.
    Thayer, R. M., M. D. Power, M. L. Bryant, M. B. Gardner, P. J. Barr, and P. A. Luciw, Sequence relationship of type D retroviruses which cause simian acquired immunodeficiency syndrome, Virology 157:317–330 (1987).PubMedCrossRefGoogle Scholar
  89. 89.
    Heidecker, G., N. W. Lerche, L. J. Lowenstine, A. A. Lackner, K. G. Osborn, M. G. Gardner, and P. A. Marx, Induction of simian acquired immune deficiency syndrome (SAIDS) with a molecular clone of a type D SAIDS virus, J. Virol. 61:3066–3071 (1987).PubMedGoogle Scholar
  90. 90.
    Marx, P. A., N. C. Pedersen, N. W. Lerche, K. G. Osborn, L. J. Lowenstine, A. A. Lackner, D. H. Maul, H.-S. Kwang, J. D. Kluge, C. P. Zaiss, V. Sharpe, A. P. Spinner, A. C. Allison, and M. B. Gardner, Prevention of simian acquired immune deficiency syn drome with a formalin-inactivated type D retrovirus vaccine, J. Virol. 60:431–435 (1986).PubMedGoogle Scholar
  91. 91.
    Daniel, M. D., N. L. Letvin, N. W. King, M. Kannagi, P. K. Schgal, R. D. Hunt, P. J. Kanki, M. Essex, and R. C. Desrosiers, Isolation of T-lymphotropic retrovirus related to HTLVIII/LAV from wild-caught African green monkeys, Science 230:951–954 (1985).CrossRefGoogle Scholar
  92. 92.
    Murphey-Corb, M., L. N. Martin, S. R. S. Rangan, G. B. Baskin, B. J. Gormus, R. H. Wolf, W. A. Andes, M. West, and R. C. Montelaro, Isolation of an HTLV-III-related retrovirus from macaques with simian AIDS and its possible origin in asymptomatic mangabeys, Nature (Lond.) 321:435–437 (1986).CrossRefGoogle Scholar
  93. 93.
    Fultz, P. N., H. M. McClure, D. C. Anderson, R. B. Swenson, R. Anand, and A. Srinivasan, Isolation of a T-lymphotropic retrovirus from naturally infected mangabeys monkeys (Cercocebus atys), Proc. Soc. Acad. Sci. USA 83:5286–5290 (1986).CrossRefGoogle Scholar
  94. 94.
    Benveniste, R. E., L. O. Arthur, C.-C. Tsai, R. Sowder, T. D. Copeland, L. E. Henderson, and S. Oroszlans, Isolation of a lentivirus from a macaque with lymphoma: Comparison with HTLV-III/LAV and lentiviruses, J. Virol. 60:483–490 (1986).PubMedGoogle Scholar
  95. 95.
    Chakrabarti, L., M. Guyader, M. Alizon, M. D. Daniel, R. C. Desrosiers, P. Tiollais, and P. Sonigo, Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses, Nature (Lond.) 328:543–546 (1987).CrossRefGoogle Scholar
  96. 96.
    Hahn, B. H., L. I. Kong, S.-W. Lee, P. Kumar, M. E. Taylor, S. K. Arya, and G. M. Shaw, Relation of HTLV-4 to simian and human immunodeficiency-associated viruses, Nature (Lond.) 330:184–187 (1987).CrossRefGoogle Scholar
  97. 97.
    Kornfeld, H., N. Riedel, G. A. Viglianti, V. Hirsh, and J. I. Mullins, Cloning of HTLV-4 and its relation to simian and human immunodeficiency viruses, Nature (Lond.) 326:610– 613 (1987).CrossRefGoogle Scholar
  98. 98.
    Hooks, J. J., and B. Detrick-Hooks, Simian foamy virus-induced immunosuppression in rabbits, J. Gen. Virol. 44:383–390 (1979).PubMedCrossRefGoogle Scholar
  99. 99.
    Weislow, O. S., O. U. Fisher, Jr., D. R. Twardzik, A. Hellman, and A. K. Fowler, Depression of mitogen-induced lymphocyte blastogenesis by baboon endogenous retro-virus-associated components, Proc. Soc. Exp. Biol. Med. 166:522–527 (1981).PubMedGoogle Scholar
  100. 100.
    Denner, J., V. Wunderlich, and D. Bierwolf, Suppression of human lymphocyte mitogen response by proteins of the type D retrovirus PMFV. Int. J. Cancer 37:311–316 (1986).PubMedCrossRefGoogle Scholar
  101. 101.
    Ceglowski, W. S., and H. Friedman, Immunosuppression by leukemia viruses. IV. Effect of Friend leukemia virus on antibody precursors as assessed by cell transfer studies, J. Immunol. 105:1406–1415 (1970).PubMedGoogle Scholar
  102. 102.
    Israel, E., B. Beiss, and M. A. Wainberg, Viral abrogation of lymphocyte mitogenesis: Induction of a soluble factor inhibitory to cellular proliferation, Immunology 40:77–85 (1980).PubMedGoogle Scholar
  103. 103.
    Israel, E., and M. A. Wainberg, Viral inhibition of lymphocyte mitogenesis: The role of macrophages as primary targets of virus-cell interaction, J. Reticuloendothel. Soc. 29:105–116 (1981).PubMedGoogle Scholar
  104. 104.
    Nicholson, J. K. A., G. D. Cross, C. S. Callaway, and J. S. McDougal. In vitro infection of human monocytes with human T lymphotropic virus type III/Lymphadenopathy-asso-ciated virus, J. Immunol 137:323–329 (1986).PubMedGoogle Scholar
  105. 105.
    Wainberg, M. A. and E. Israel, Viral inhibition of lymphocyte mitogenesis. I. Evidence for the nonspecificity of the effect, J. Immunol. 124:64–70 (1980).PubMedGoogle Scholar
  106. 106.
    Bubbers, J. E., J. H. Elder, and F. J. Dixon, Stimulation of murine lymphocytes by Rauscher leukemia virus in vitro, J. Immunol. 124:388–394 (1980).PubMedGoogle Scholar
  107. 107.
    Orosz, C. G., N. E. Zinn, R. G. Olsen, and L. E. Mathes, Retrovirus-mediated immu nosuppression. II. FeLV-UV alters in vitro murine T lymphocyte behavior by reversibly impairing lymphokine secretion, J. Immunol. 135:583–590 (1985).PubMedGoogle Scholar
  108. 108.
    Schmidt, D. M., N. K. Sidhu, G. J. Cianciolo, and R. Snyderman, Recombinant hydro-philic region of murine retroviral protein pl5E inhibits stimulated T-lymphocyte proliferation, Proc. Natl Acad. Sci. USA 84:7290–7294 (1987).PubMedCrossRefGoogle Scholar
  109. 109.
    Harris, D. T., G. J. Cianciolo, R. Snyderman, S. Argov, and H. S. Koren, Inhibition of human natural killer cell activity by a snythetic peptide homologous to a conserved region in the retroviral protein, pl5E, J. Immunol. 138:889–894 (1987).Google Scholar
  110. 110.
    Kleinerman, E. S., L. B. Lachman, R. D. Knowles, R. Snyderman, and G. J. Cianciolo, A synthetic peptide homologous to the envelope proteins of retroviruses inhibits mono-cyte-mediated killing by inactivating interleukin 1, J. Immunol. 139:2329–2337 (1987).PubMedGoogle Scholar
  111. 111.
    Roder, J. C., L. Tyler, J. K. Ball, and S. K. Singhal, The immunocompetence of tumor T cells and their role in generalized immunosuppression and immunostimulation following inoculation of dimethylbenzanthracene-induced leukemia virus in mice, Cell. Immunol. 36:128–142 (1978).PubMedCrossRefGoogle Scholar
  112. 112.
    Grinwich, K. D., T. S. Alexander, and J. Cerny, Properties of murine leukemia-associated suppressor cells. I. Preferential suppression of thymus-dependent antibody responses and the requirement for syngenicity in the K region of the H-2 complex, J. Immunol. 122:1108–1115 (1979).PubMedGoogle Scholar
  113. 113.
    Tagliabue, A., D. Boraschi, and J. L. McCoy, Development of cell-mediated antiviral immunity and macrophage activation in C3H/HeN mice infected with mouse mammary tumor virus, J. Immunol. 124:2203–2208 (1980).PubMedGoogle Scholar
  114. 114.
    Yefenof, E., and J. Ben-David, Suppressor and reactive lymphocytes in radiation leukemia virus-induced leukemogenesis, Cancer Immunol. Immunother. 16:48–52 (1983).PubMedCrossRefGoogle Scholar
  115. 115.
    Tilkin, A.-F., B. Begue, E. Gomard, and J.-P. Levy, Natural suppressor cell inhibiting T killer responses against retroviruses: A model for self-tolerance, J. Immunol. 134:2779– 2782 (1985).PubMedGoogle Scholar
  116. 116.
    Mosier, D. E., R. A. Yetter, and H. C. Morse, Functional T lymphocytes are required for a murine retrovirus-induced immunodeficiency disease (MAIDS), J. Exp. Med. 165:1738– 1742 (1987).CrossRefGoogle Scholar
  117. 117.
    Garaci, E., G. Migliorati, T. Jezzi, A. Bartocci, L. Gioia, C. Rinaldi, and E. Bonmassar, Impairment of in vitro generation of cytotoxic or T suppressor lymphocytes by Friend leukemia virus infection in mice, Int. J. Cancer 28:367–373 (1981).PubMedCrossRefGoogle Scholar
  118. 118.
    Stiff, M. and R. Olsen, Loss of short-lived suppressive function of peripheral leukocytes in feline retrovirus-infected cats, J. Clin. Lab. Immunol. 7:133–138 (1982).PubMedGoogle Scholar
  119. 119.
    Rudczynski, A. B., and R. F. Mortensen, Suppressor cells in mice with murine mammary tumor virus-induced mammary tumors. I. Inhibition of mitogen-induced lymphocyte stimulation, J. Natl. Cancer Inst. 60:205–211 (1978).PubMedGoogle Scholar
  120. 120.
    Bendinelli, M., D. Matteucci, A. Toniolo, and H. Friedman, Suppression of in vitro antibody response by spleen cells of mice infected with Friend-associated lymphatic leukemia virus, Infect. Immun. 24:1–6 (1979).PubMedGoogle Scholar
  121. 121.
    Spickett, G. P., and A. G. Dalgleish, Cellular immunology of HIV-infection, Clin. Exp. Immunol. 71:1–7 (1987).Google Scholar
  122. 122.
    Tonietti, G., G. B. Rossi, V., Gobbo, L. Accinni, A. Ranucci, F. Titti, M. G. Premrov, and E. Garaci, Effects of in vivo Friend leukemia virus infection on levels of serum thymic factors and on selected T-cell functions in mice, Cancer Res. 43:4355–4363 (1983).PubMedGoogle Scholar
  123. 123.
    Blank, K. J., and D. M. Murasko, Induction of interferon in AKR mice by various murine leukaemia viruses, Nature (Lond.) 283:494–495 (1980).CrossRefGoogle Scholar
  124. 124.
    Rodgers, B. C., D. M. Scott, J. Mundin, and J. G. P. Sissons, Monocyte-derived inhibitor of interleukin 1 induced by human cytomegalovirus, J. Virol. 55:527–532 (1985).PubMedGoogle Scholar
  125. 125.
    Hardy, W. D., Jr., Feline retroviruses, in: Advances in Viral Oncology ,Vol. 5: Viruses as the Causative Agents of Naturally Occurring Tumors (G. Klein, ed.), pp. 1–34, Raven, New York (1985).Google Scholar
  126. 126.
    Ruprecht, R. M., L. D. Rossoni, W. A. Haseltine, and S. Broder, Suppression of retro viral propagation and disease by suramin in murine systems, Proc. Natl. Acad. Sci. USA 82:7733–7737 (1985).PubMedCrossRefGoogle Scholar
  127. 127.
    Mitsuya, H., and S. Broder, Strategies for antiviral therapies in AIDS, Nature (Lond.) 325:773–778 (1987).CrossRefGoogle Scholar
  128. 128.
    Mitsuya, H., R. F. Jarret, M. Matsukura, F. Di Marzio Veronese, A. L. DeVico, M. G. Sarngadharan, D. G. Johns, M. S. Reitz, and S. Broder, Longterm inhibition of human T-lymphotropic virus type III/Lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2’,3’-dideoxynucleosides in vitro, Proc. Natl. Acad. Sci. USA 84:2033–2037 (1987).PubMedCrossRefGoogle Scholar
  129. 129.
    Genovesi, E. V., D. Livnat, and J. J. Collins, Immunotherapy of murine leukemia. VIII. Efficacy of passive serum therapy of Friend leukemia virus-induced disease in immunocompromised mice, J. Natl. Cancer Inst. 70:311–322 (1983).PubMedGoogle Scholar
  130. 130.
    David, Y. B., M. Kotler, and E. Yefenof, A highly leukemogenic radiation leukemia virus isolate is a thymotropic, immunosuppressive retrovirus with a unique RNA structure, Int. J. Cancer 39:495–497 (1987).Google Scholar
  131. 131.
    Larson, C. L., R. E. Baker, R. N. Ushijima, H. B. Baker, and C. Gillespie, Immunotherapy of Friend disease in mice employing viable BCG vaccine, Proc. Soc. Exp. Biol. Med. 140:700–702 (1972).PubMedGoogle Scholar
  132. 132.
    Sklaroff, D. M., S. J. DeCourcy, Jr., S. Specter, and H. Friedman, Suppressed development of mammary tumorigenesis in RIII mice treated neonatally with BCG, Proc. Soc. Exp. Biol. Med. 158:235–237 (1978).PubMedGoogle Scholar
  133. 133.
    Wleklik, M., S. B. Levy, M. Luczak, and V. A. Najjar, Suppression of Friend virus-induced leukaemia in mice by tuftsin, J. Gen. Virol. 67:2001–2004 (1986).PubMedCrossRefGoogle Scholar
  134. 134.
    Liu, W. T., R. A. Good, L. Q. Trang, R. W. Engleman, and N. K. Day, Remission of leukemia and loss of feline leukemia virus in cats injected with Staphylococcus protein A: Association with increased circulating interferon and complement-dependent antibody, Proc. Natl. Acad. Sci. USA 81:6471–6475 (1984).PubMedCrossRefGoogle Scholar
  135. 135.
    Snyder, H. W., Jr., M. C. Singhal, W. D. Hardy, Jr., and F. R. Jones, Clearance of feline leukemia virus from persistently infected pet cats treated by extracorporeal immunoad-sorption is correlated with an enhanced antibody response to FeLV gp 70, J. Immunol. 132:1538–1543 (1984).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • Steven Specter
    • 1
  • Mauro Bendinelli
    • 2
  • Herman Friedman
    • 1
  1. 1.Department of Medical Microbiology and Immunology, College of MedicineUniversity of South FloridaTampaUSA
  2. 2.Department of BiomedicineUniversity of PisaPisaItaly

Personalised recommendations